A large, multi‑billion‑dollar medical device manufacturer was producing high‑volume components for global markets under EU MDR, and FDA‑regulated conditions. The company relied heavily on third‑party sterilization partners to keep products flowing through the supply chain.
The problem
The manufacturer’s primary sterilization vendor had developed a six‑month backlog, creating a severe bottleneck. Finished components sat in inventory, tying up cash and delaying shipments to hospitals and distributors.
Quality teams worried about compliance risk if they rushed alternative options.
Operations needed predictable lead times to keep production lines running.
Supply chain leaders saw revenue impact and growing customer dissatisfaction from delayed deliveries.
Product contamination due exposure over months could resulted in lower shelf life.
In short: product was ready to sell, but sterilization capacity prevented it from reaching the market.
The partner they needed
The OEM looked for a sterilization partner that could:
Offer FDA‑registered, ISO‑aligned sterilization capacity.
Onboard quickly without compromising compliance or documentation quality.
Handle high‑volume, ongoing throughput rather than a one‑time overflow project.
This aligned closely with the needs of both Quality/Regulatory leaders and Operations/Supply‑Chain leaders who needed reliability, speed, and audit‑ready processes.
The solution
Advasaf, the new sterilization provider engaged with the OEM across Quality, Regulatory, and Operations to remove the bottleneck.
Rapid technical and quality onboarding
Reviewed existing sterilization validations, specifications, and risk assessments.
Mapped the provider’s processes to the OEM’s QMS requirements and audit expectations.
Capacity and scheduling redesign
Re‑planned loads to absorb overflow while preserving room for growth.
Defined predictable turnaround times with lean processes so Operations could update production schedules and customer commitments.
Integrated service bundle
Coordinated sterilization, packaging support, and logistics to minimize extra handling steps.
Ensured all documentation met internal and FDA, EU CE, and customer QMS expectations for compliance and inspections.
The results
Within weeks, the OEM saw clear operational and compliance gains:
Backlog reduction: Significant volume moved through the new sterilization line within days rather than the six‑month wait at the original vendor.
Supply‑chain stability: Operations regained predictable lead times, improving customer commitments and production planning.
Compliance confidence: Quality and Regulatory teams had audit‑ready documentation and a clearly FDA‑aligned sterilization partner.
Over time, the provider shifted from “overflow vendor” to a strategic dual‑sourcing partner that helped protect the OEM from future bottlenecks and market disruptions.